Physician profile
Alan Dang
NPI 1043217359
$14,159.93
in general payments reported to CMS, 2019-2025
49 companies · $3,245 in 2025
The $3,245 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,397 · 2020: $643 · 2021: $1,395 · 2022: $1,365 · 2023: $1,926 · 2024: $2,190 · 2025: $3,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,360.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,520.88 | 2019-2023 | Vraylar, Lo Loestrin Fe, Liletta |
| Amgen INC. | $1,818.39 | 2019-2025 | Evenity, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $609.79 | 2019-2024 | Lokelma, Airsupra |
| Neurocrine Biosciences, INC. | $583.16 | 2019-2023 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $471.49 | 2024 | Voquezna |
| Lilly USA, LLC | $461.24 | 2019-2025 | Jardiance |
| Mayne Pharma Commercial LLC | $452.32 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $370.90 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $370.12 | 2021-2025 | Caplyta |
| Allergan, INC. | $359.43 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.18 | 2019-2021 | |
| Insulet Corporation | $315.03 | 2025 | Omnipod |
| Janssen Pharmaceuticals, INC | $309.51 | 2019-2021 | |
| Abbott Laboratories | $284.44 | 2025 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit |
| Axsome Therapeutics, INC. | $274.57 | 2024-2025 | Auvelity |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $268.57 | 2021-2024 | Talicia |
| Gilead Sciences, INC. | $259.85 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $250.00 | 2024-2025 | Fanapt |
| Myovant Sciences INC. | $249.25 | 2021-2022 | |
| Alkermes, INC. | $214.02 | 2022-2023 | Lybalvi |
| Amarin Pharma, INC. | $210.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $199.70 | 2023-2024 | Rexulti |
| Ethicon US, LLC | $193.29 | 2019-2021 | |
| Abiomed | $180.73 | 2024-2025 | Impella |
| Novo Nordisk INC | $163.39 | 2021-2022 | |
| Genzyme Corporation | $149.46 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.10 | 2025 | |
| Averitas Pharma INC. | $140.29 | 2024 | Qutenza |
| Scilex Pharmaceuticals INC. | $136.03 | 2024 | |
| Sanofi Pasteur INC. | $127.24 | 2019 | |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Exact Sciences Corporation | $125.00 | 2025 | The Cologuard Plus Collection Kit |
| Acadia Pharmaceuticals INC | $124.99 | 2019 | |
| Sumitomo Pharma America, INC. | $124.51 | 2023 | Myfembree |
| Roche Diagnostics Corporation | $122.35 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $121.37 | 2019 | |
| Therapeuticsmd, INC. | $119.57 | 2019 | |
| Glaxosmithkline, LLC. | $118.44 | 2022 | |
| Corcept Therapeutics | $112.43 | 2023 | Korlym |
| Radius Health, INC. | $106.93 | 2025 | Tymlos |
| Astellas Pharma US INC | $105.43 | 2023 | Veozah |
| Inari Medical, INC. | $92.78 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kestra Medical Technology Services, INC. | $83.34 | 2024 | Assure Wcd |
| Organon LLC | $71.57 | 2021-2024 | Nexplanon |
| Aspira Women'S Health INC | $53.75 | 2019-2023 | Ova1 |
| Dexcom, INC. | $40.97 | 2025 | Dexcom G6 Transmitter |
| Avion Pharmaceuticals | $40.23 | 2021 | |
| Pfizer INC. | $33.59 | 2021 | |
| Mylan Pharmaceuticals INC. | $16.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.